Drug-Resistant Cholangiocarcinoma Cell Lines for Therapeutic Evaluation of Novel Drugs
Molecules · 2025
DOI: 10.3390/molecules30143053 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecules, 2025. Verfasst von Kevin Delgado-Calvo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Hepatology and Drug Targeting (HEVEPHARM) Group, Institute of Biomedical Research of Salamanca (IBSAL), Center for the Study of Liver an…. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Drug Resistance, Neoplasm, Antineoplastic Agents, Bile Duct Neoplasms. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Junta de Castilla y León.
Abstract (Originalsprache)
The pharmacological treatment of cholangiocarcinoma (CCA) is often hampered by tumor resistance. Improving our understanding of this issue is crucial for developing strategies that can overcome drug refractoriness. We have established and characterized two novel human cell sublines derived from extrahepatic CCA EGI-1 cells that are resistant to cisplatin and 5-fluorouracil (5-FU). Migration and proliferation were analyzed using holographic microscopy. The expression of genes involved in drug uptake and efflux was determined by RT-qPCR. Cross-resistance to commonly used antitumor drugs was assayed using the MTT test. EGI-1 sublines resistant to cisplatin (CR) or 5-FU (FR) exhibited more than a three-fold increase in resistance to cisplatin and 5-FU, respectively, and showed reduced proliferation, migration, and colony-formation rates, along with an altered cell cycle compared to wild-type cells, while retaining tumorigenic capacity. The analysis of the transportome showed downregulation of uptake transporters and upregulation of the export pumps MRP3/4. EGI-1 cells with acquired resistance to 5-FU demonstrated cross-resistance to irinotecan and gemcitabine, while cisplatin-resistant cells showed decreased sensitivity to 5-FU and platinum derivatives. These resistant cell lines offer valuable models for investigating the molecular basis of chemoresistance in CCA, providing a robust platform for the development and evaluation of novel therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Experimental Hepatology and Drug Targeting (HEVEPHARM) Group, Institute of Biomedical Research of Salamanca (IBSAL), Center for the Study of Liver and Gastrointestinal Diseases (CIBERehd), University of Salamanca, Campu…
- Department of Health Sciences, University of Piemonte Orientale, 28100 Novara, Italy.
- Hepatobiliary Immunopathology Laboratory, IRCCS Humanitas Research Hospital, Rozzano, 20089 Milan, Italy.
ORCID-Profile: Kevin Delgado-Calvo, Elisa Lozano, Oscar Briz, Candela Cives-Losada, Jose J G Marin, Rocio I R Macias
Förderung
- Instituto de Salud Carlos III
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas
- Junta de Castilla y León
- AECC Scientific Foundation
- CIBEREHD
- Junta de Castilla y Leon
Zitieren
APA
Delgado-Calvo, K., Lozano, E., Briz, O., Cives-Losada, C., Marin, J. J. G., & Macias, R. I. R. (2025). Drug-Resistant Cholangiocarcinoma Cell Lines for Therapeutic Evaluation of Novel Drugs. Molecules. https://doi.org/10.3390/molecules30143053
Vancouver
Delgado-Calvo K, Lozano E, Briz O, Cives-Losada C, Marin JJG, Macias RIR. Drug-Resistant Cholangiocarcinoma Cell Lines for Therapeutic Evaluation of Novel Drugs. Molecules. 2025. doi:10.3390/molecules30143053
BibTeX
@article{DelgadoCalvo2025,
author = {Delgado-Calvo, Kevin and Lozano, Elisa and Briz, Oscar and Cives-Losada, Candela and Marin, Jose J G and Macias, Rocio I R},
title = {Drug-Resistant Cholangiocarcinoma Cell Lines for Therapeutic Evaluation of Novel Drugs},
journal = {Molecules},
year = {2025},
doi = {10.3390/molecules30143053}
}
EUVIMED